Holen Sie sich die Stockscreener-App
8.01
4.29%
-0.38
Handel nachbörslich:
8.01
Schlusskurs vom Vortag:
$8.39
Offen:
$8.29
24-Stunden-Volumen:
67,512
Relative Volume:
0.75
Marktkapitalisierung:
$771.47M
Einnahmen:
$106.66M
Nettoeinkommen (Verlust:
$15.16M
KGV:
85.67
EPS:
0.0935
Netto-Cashflow:
$6.37M
1W Leistung:
+10.45%
1M Leistung:
+2.55%
6M Leistung:
+4.02%
1J Leistung:
-39.81%
1-Tages-Spanne:
$7.98
$8.39
1-Wochen-Bereich:
$7.15
$8.50
52-Wochen-Spanne:
$6.11
$19.00
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Firmenname
Gyre Therapeutics Inc
Sektor
Branche
Telefon
(619) 949-3681
Adresse
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Vergleichen Sie GYRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
8.01 | 762.04M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | Jefferies | Buy |
| 2025-08-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-11 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-04-29 | Fortgesetzt | Stephens | Overweight |
| 2021-02-10 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-21 | Eingeleitet | Raymond James | Outperform |
| 2019-01-04 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-12 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-12-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-06-06 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-06-30 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Gyre Therapeutics Inc Aktie (GYRE) Neueste Nachrichten
Using Ichimoku Cloud for Gyre Therapeutics Inc. technicalsWeekly Stock Summary & Verified Momentum Stock Alerts - newser.com
High Growth US Tech Stocks To Watch In October 2025 - Yahoo Finance
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD-The Liver Meeting® 2025 - The Manila Times
Gyre Therapeutics to Present Positive Phase 3 Trial Results of Hydronidone for Liver Fibrosis at The Liver Meeting® 2025 - Quiver Quantitative
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025 - Stock Titan
Will breakout in Gyre Therapeutics Inc. lead to full recovery2025 AllTime Highs & Low Drawdown Investment Strategies - newser.com
What dividend safety score for Gyre Therapeutics Inc. stockPortfolio Value Summary & Weekly Market Pulse Updates - newser.com
How to integrate Gyre Therapeutics Inc. into portfolio analysis toolsJuly 2025 Selloffs & Accurate Technical Buy Alerts - newser.com
Using fundamentals and technicals on Gyre Therapeutics Inc.Stop Loss & Fast Gain Stock Trading Tips - newser.com
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up – Should You Buy? - Defense World
What momentum shifts mean for Gyre Therapeutics Inc.2025 Dividend Review & Technical Buy Zone Confirmation - newser.com
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap UpHere's Why - MarketBeat
Gyre Therapeutics Stock Price, Quotes and Forecasts - Benzinga
Jefferies initiates Gyre Therapeutics stock with Buy rating, $16 target By Investing.com - Investing.com Nigeria
Visual trend scoring systems applied to Gyre Therapeutics Inc.2025 Valuation Update & Risk Controlled Stock Pick Alerts - newser.com
This Aptiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Jefferies Initiates Coverage on Gyre Therapeutics (GYRE) with a "Buy" Rating | GYRE Stock News - GuruFocus
Jefferies Initiates Coverage of Gyre Therapeutics (GYRE) with Buy Recommendation - Nasdaq
Jefferies initiates Gyre Therapeutics stock with Buy rating, $16 target - Investing.com
Gyre Therapeutics (NASDAQ:GYRE) Earns Sell (D) Rating from Weiss Ratings - MarketBeat
Gyre Therapeutics Inc Stock Analysis and ForecastCandlestick Pattern Analysis & Small Investment Portfolio - earlytimes.in
Can momentum traders help lift Gyre Therapeutics Inc.Weekly Trend Report & Safe Entry Point Identification - newser.com
Gyre Therapeutics Inc. stock outlook for YEARJuly 2025 Big Picture & Low Drawdown Investment Ideas - newser.com
Volatility clustering patterns for Gyre Therapeutics Inc.Portfolio Value Summary & Short-Term Swing Trade Alerts - newser.com
Real time alert setup for Gyre Therapeutics Inc. performanceTrade Risk Report & Free Expert Approved Momentum Trade Ideas - newser.com
Gyre Therapeutics president Ma Songjiang sells $42,760 in stock - MSN
Discovering 3 Undiscovered Gems In The US Market - simplywall.st
Goldman Sachs Group Inc. Cuts Stock Position in Gyre Therapeutics, Inc. $GYRE - Defense World
Developing predictive dashboards with Gyre Therapeutics Inc. dataPortfolio Performance Report & AI Forecast Swing Trade Picks - newser.com
What analysts say about Gyre Therapeutics Inc stockStock Valuation Metrics & Free Quantitative Trading Strategies - earlytimes.in
Gyre Therapeutics president sells $45,380 in stock - MSN
Is Gyre Therapeutics Inc a good long term investmentEarnings Forecast Updates & Free Dynamic Capital Growth - earlytimes.in
Finanzdaten der Gyre Therapeutics Inc-Aktie (GYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gyre Therapeutics Inc-Aktie (GYRE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ma Songjiang | President |
May 28 '25 |
Sale |
10.07 |
558 |
5,619 |
2,806,084 |
| Ma Songjiang | President |
May 22 '25 |
Sale |
10.97 |
2,000 |
21,940 |
2,808,824 |
| Ma Songjiang | President |
May 23 '25 |
Sale |
10.24 |
182 |
1,864 |
2,808,642 |
| Ma Songjiang | President |
May 20 '25 |
Sale |
11.25 |
2,000 |
22,500 |
2,812,824 |
| Ma Songjiang | President |
May 21 '25 |
Sale |
10.83 |
2,000 |
21,660 |
2,810,824 |
| Ma Songjiang | President |
May 16 '25 |
Sale |
11.31 |
2,000 |
22,620 |
2,816,824 |
| Ma Songjiang | President |
May 19 '25 |
Sale |
11.11 |
2,000 |
22,220 |
2,814,824 |
| Ma Songjiang | President |
May 15 '25 |
Sale |
10.68 |
2,000 |
21,360 |
2,818,824 |
| Ma Songjiang | President |
May 14 '25 |
Sale |
11.30 |
20 |
226 |
2,820,824 |
| Ye Weiguo | Chief Operating Officer |
Apr 01 '25 |
Option Exercise |
0.75 |
50,000 |
37,500 |
700,000 |
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):